2. Amyotrophic lateral sclerosis Clinical trials / Disease details
Clinical trials : 624 / Drugs : 611 - (DrugBank : 160) / Drug target genes : 172 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04391361 (ClinicalTrials.gov) | November 1, 2020 | 13/5/2020 | The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of ALS | The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis;Respiratory Function;Scopolamine | Drug: Scopolamine, atropine, edaravone and dexmedetomidine;Drug: Edaravone | Ruijin Hospital | NULL | Not yet recruiting | 30 Years | 65 Years | All | 30 | Phase 2 | China |